Diruthenium(II-III)-ibuprofen-loaded chitosan-based microparticles and nanoparticles systems: encapsulation, characterisation, anticancer activity of the nanoformulations against U87MG human glioma cells

References

• Alessio, E. and Guo, Z., 2017. Metal anticancer complexes – activity, mechanism of action, future perspectives. European journal of inorganic chemistry, 2017 (12), 1539–1540. doi: 10.1002/ejic.201700196.
   Google Scholar
• Alessio, E. and Messori, L., 2019. NAMI-A and KP1019/1339, two iconic ruthenium anticancer drug candidates face-to-face: A case story in medicinal inorganic chemistry. Molecules, 24 (10), 1995. doi: 10.3390/molecules24101995.
   PubMed Web of Science ®Google Scholar
• Alves, S.R., et al., 2020. Synthesis of terpolymer-lipid encapsulated diruthenium(II,III)-antiinflammatory metallodrug nanoparticles to enhance activity against glioblastoma cancer cells. Journal of inorganic biochemistry, 205, 110984. doi: 10.1016/j.jinorgbio.2019.110984.
   PubMed Web of Science ®Google Scholar
• Alves, S.R., et al., 2021. A novel μ-oxo-diruthenium(III,III)-ibuprofen-(4-aminopyridine) chloride derived from the diruthenium(II,III)-ibuprofen paddlewheel metallodrug shows anticancer properties. Journal of inorganic biochemistry, 225, 111596. doi: 10.1016/j.jinorgbio.2021.111596.
   PubMed Web of Science ®Google Scholar
• Amirthaganesan, K., et al., 2022. In vitro antifungal studies of Ruthenium (III) complex derived from chitosan Schiff bases. Materials today, 60, 1716–1720. doi: 10.1016/j.matpr.2021.12.265.
   Google Scholar
• Andrade, A., et al., 2000. Synthesis and characterization of a diruthenium–ibuprofenato complex Comparing its anti-inflammatory activity with that of a copper(II)–ibuprofenato complex. Journal of inorganic biochemistry, 81 (1–2), 23–27. doi: 10.1016/s0162-0134(00)00106-9.
   PubMed Web of Science ®Google Scholar
• Ang, W.H. and Dyson, P.J., 2006. Classical and non-classical ruthenium-based anticancer drugs: towards targeted chemotherapy. European journal of inorganic chemistry, 20, 3993–4000. doi: 10.1002/ejic.200600723.
   Google Scholar
• Baklagina, Y.G., et al., 2018. Polymorphic modifications of chitosan. Crystallography reports, 63 (3), 303–313. doi: 10.1134/S1063774518030033.
   Web of Science ®Google Scholar
• Benadiba, M., et al., 2010. Inhibition of C6 rat glioma proliferation by [Ru2Cl(Ibp)4] depends on changes in p21, p27, Bax/Bcl2 ratio and mitochondrial membrane potential. Journal of inorganic biochemistry, 104 (9), 928–935. doi: 10.1016/j.jinorgbio.2010.04.011.
   PubMed Web of Science ®Google Scholar
• Benadiba, M., et al., 2014. Growth inhibitory effects of the diruthenium-ibuprofen compound, [Ru2Cl(Ibp)4], in human glioma cells in vitro and in the rat C6 orthotopic glioma in vivo. Journal of biological inorganic chemistry, 19 (6), 1025–1035. doi: 10.1007/s00775-014-1143-4.
   PubMed Web of Science ®Google Scholar
• Bergamo, A., et al., 2012. Approaching tumour therapy beyond platinum drugs status of the art and perspectives of ruthenium drug candidates. Journal of inorganic biochemistry, 106 (1), 90–99. doi: 10.1016/j.jinorgbio.2011.09.030.
   PubMed Web of Science ®Google Scholar
• Bhumkar, R.D., and Pokharkar, V.B., 2006. Studies on effect of pH on cross-linking of chitosan with sodium tripolyphosphate: a technical note. AAPS PharmSciTech, 7 (2), E50–E143. doi: 10.1208/pt070250.
   PubMed Web of Science ®Google Scholar
• Blunden, B.M., et al., 2014. Superior chemotherapeutic benefits from the ruthenium-based anti-metastatic drug NAMI‑A through conjugation to polymeric micelles. Macromolecules, 47 (5), 1646–1655. doi: 10.1021/ma402078d.
   Web of Science ®Google Scholar
• Boztepe, T., Castro, G.R., and León, I.E., 2021. Lipid, polymeric, inorganic-based drug delivery applications for platinum-based anticancer drugs. International journal of pharmaceutics, 605, 120788. doi: 10.1016/j.ijpharm.2021.120788.
   PubMed Web of Science ®Google Scholar
• Brabec, V. and Kasparkova, J., 2018. Ruthenium coordination compounds of biological and biomedical significance. DNA binding agents. Coordination chemistry reviews, 376, 75–94. doi: 10.1016/j.ccr.2018.07.012.
   Web of Science ®Google Scholar
• Braccini, I. and Pérez, S., 2001. Molecular basis of Ca2+-induced gelation in alginates and pectins: the Egg-Box model revisited. Biomacromolecules, 2 (4), 1089–1096. doi: 10.1021/bm010008g.
   PubMed Web of Science ®Google Scholar
• Buyana, B., et al., 2022. Nanoparticles loaded with platinum drugs for colorectal cancer therapy. International journal of molecular sciences, 23 (19), 11261. doi: 10.3390/ijms231911261.
   PubMed Web of Science ®Google Scholar
• Calvo, P., et al., 1997. Novel hydrophilic chitosan–polyethylene oxide nanoparticles as protein carriers. Journal of applied polymer science, 63 (1), 125–132. doi: 10.1002/(SICI)1097-4628(19970103)63:1<125::AID-APP13>3.0.CO;2-4.
   Web of Science ®Google Scholar
• Caprifico, A.E., et al., 2020. Overcoming the blood-brain barrier: functionalised chitosan nanocarriers. Pharmaceutics, 12 (11), 1013. doi: 10.3390/pharmaceutics12111013.
   PubMed Web of Science ®Google Scholar
• Coverdale, J.P.C., Laroiya-McCarron, T., and Canelón, I.R., 2019. Designing ruthenium anticancer drugs: what have we learnt from the key drug candidates? Inorganics, 7 (3), 31. doi: 10.3390/inorganics7030031.
   Web of Science ®Google Scholar
• Dash, M., et al., 2011. Chitosan-A versatile semi-synthetic polymer in biomedical applications. Progress in polymer science, 36 (8), 981–1014. doi: 10.1016/j.progpolymsci.2011.02.001.
   Web of Science ®Google Scholar
• de Oliveira Silva, D., 2010. Perspectives for novel mixed diruthenium-organic drugs as metallopharmaceuticals in cancer therapy. Anti-cancer agents in medicinal chemistry, 10 (4), 312–323. doi: 10.2174/187152010791162333.
   PubMed Web of Science ®Google Scholar
• de Oliveira Silva, D., 2014. Ruthenium compounds targeting cancer therapy. In: Atta-ur-Rahman and M.I. Choudhary, eds. Frontiers in anti-cancer drug discovery. Vol. 4. United Arab Emirates: Bentham Science Publishers, 88–156.
   Google Scholar
• El-Banna, F., et al., 2019. Chitosan as a natural copolymer with unique properties for the development of hydrogels. Applied sciences, 9, 2193. doi: 10.3390/app9112193.
   Google Scholar
• Eslahi, M., et al., 2021. The effects of chitosan-based materials on glioma: recent advances in its applications for diagnosis and treatment. International journal of biological macromolecules, 168, 124–129. doi: 10.1016/j.ijbiomac.2020.11.180.
   PubMed Web of Science ®Google Scholar
• Fischer, B., et al., 2014. Poly(lactic acid) nanoparticles of the lead anticancer ruthenium compound KP1019 and its surfactant-mediated activation. Dalton transactions, 43 (3), 1096–1104. doi: 10.1039/c3dt52388h.
   PubMed Web of Science ®Google Scholar
• Gao, J., et al., 2018. High performance shape-stabilized phase change material with nanoflower-like wrinkled mesoporous silica encapsulating polyethylene glycol: preparation and thermal properties. Nanomaterials, 8 (6), 385. doi: 10.3390/nano8060385.
   Web of Science ®Google Scholar
• Garg, U., et al., 2019. Current advances in chitosan nanoparticles based drug delivery and targeting. Advanced pharmaceutical bulletin, 9 (2), 195–204. doi: 10.15171/apb.2019.023.
   PubMed Web of Science ®Google Scholar
• González, Y.A.G., and Triviño, G.C., 2022. New chitosan-based chemo pharmaceutical delivery systems for tumor cancer treatment: short-review. Journal of the Chilean chemical society, 67, 5425–5432.
   Web of Science ®Google Scholar
• Gou, Y., et al., 2021. Versatile delivery systems for non-platinum metal-based anticancer therapeutic agents. Coordination chemistry reviews, 441, 213975. doi: 10.1016/j.ccr.2021.213975.
   Web of Science ®Google Scholar
• Hartinger, C.G., Metzler-Nolte, N., and Dyson, P.J., 2012. Challenges and opportunities in the development of organometallic anticancer drugs. Organometallics, 31 (16), 5677–5685. doi: 10.1021/om300373t.
   Web of Science ®Google Scholar
• Kim, J., et al., 2015. Polymeric biomaterials for the delivery of platinum-based anticancer drugs. Biomaterials science, 3 (7), 1002–1017. doi: 10.1039/c5bm00039d.
   PubMed Web of Science ®Google Scholar
• Kim, S., 2011. Chitin, chitosan, oligosaccharides and their derivatives-biological activities and applications. Boca Raton: CRC Press Taylor & Francis Group.
   Google Scholar
• Li, J., et al., 2018. Chitosan-based nanomaterials for drug delivery. Molecules, 23 (10), 2661. doi: 10.3390/molecules23102661.
   PubMed Web of Science ®Google Scholar
• Li, X., et al., 2009. Characterization and biodegradation of chitosan–alginate polyelectrolyte complexes. Polymer degradation and stability, 94 (1), 1–6. doi: 10.1016/j.polymdegradstab.2008.10.017.
   Web of Science ®Google Scholar
• Liu, Y., et al., 2021. Chitosan-based self-assembled nanomaterials: their application in drug delivery. View, 2 (1), 20200069. doi: 10.1002/VIW.20200069.
   Google Scholar
• Lu, Y., et al., 2022. Ruthenium-based antitumor drugs and delivery systems from monotherapy to combination therapy. Nanoscale, 14 (44), 16339–16375. doi: 10.1039/d2nr02994d.
   PubMed Web of Science ®Google Scholar
• Luo, Y., and Wang, Q., 2014. Recent development of chitosan-based polyelectrolyte complexes with natural polysaccharides for drug delivery. International journal of biological macromolecules, 64, 353–367. doi: 10.1016/j.ijbiomac.2013.12.017.
   PubMed Web of Science ®Google Scholar
• Maeda, H., et al., 2000. Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. Journal of controlled release, 65 (1–2), 271–284. doi: 10.1016/s0168-3659(99)00248-5.
   PubMed Web of Science ®Google Scholar
• Martins, A.F., et al., 2012. Chitosan/TPP microparticles obtained by microemulsion method applied in controlled release of heparin. International journal of biological macromolecules, 51 (5), 1127–1133. doi: 10.1016/j.ijbiomac.2012.08.032.
   PubMed Web of Science ®Google Scholar
• Martins, D.J., et al., 2015. Interaction of chitosan beads with a copper- naproxen metallodrug. RSC advances, 5, 90184–90192. doi: 10.1039/C5RA16878C.
   Web of Science ®Google Scholar
• Messori, L., et al., 2014. Unusual structural features in the lysozyme derivative of the tetrakis(acetato)chloridodiruthenium(II,III) complex.Angewandte chemie, 53 (24) 6172–6175. doi: 10.1002/anie.201403337.
   Google Scholar
• Mikušová, V., and Mikuš, P.J., 2021. Advances in chitosan-based nanoparticles for drug delivery. International journal of molecular sciences, 22 (17), 9652. doi: 10.3390/ijms22179652.
   PubMed Web of Science ®Google Scholar
• Miyake, J.A., et al., 2014. Novel ruthenium-gamma-linolenic acid complex inhibits C6 rat glioma cell proliferation in vitro and in the orthotopic C6 model in vivo after osmotic pump infusion. Anticancer research, 34, 1901–1912.
   PubMed Web of Science ®Google Scholar
• Nascimento, R.R., et al., 2023. Poly(lactic acid)/β-cyclodextrin based nanoparticles bearing ruthenium(II)-arene naproxen complex: preparation and characterisation. Analytical validation for metal determination by microwave-induced plasma optical emission spectrometry. Journal of microencapsulation, 40, 67–81. doi: 10.1080/02652048.2023.2172469.
   PubMed Web of Science ®Google Scholar
• Nazarov, A.A., Hartinger, C.G., and Dyson, P.J., 2014. Opening the lid on piano-stool complexes: An account of ruthenium(II)-arene complexes with medicinal applications. Journal of organometallic chemistry, 751, 251–260. doi: 10.1016/j.jorganchem.2013.09.016.
   Web of Science ®Google Scholar
• Okuyama, K., et al., 1997. Molecular and crystal structure of hydrated chitosan. Macromolecules, 30 (19), 5849–5855. doi: 10.1021/ma970509n.
   Web of Science ®Google Scholar
• Paques, J.P., et al., 2014. Preparation methods of alginate nanoparticles. Advances in colloid and interface science, 209, 163–171. doi: 10.1016/j.cis.2014.03.009.
   PubMed Web of Science ®Google Scholar
• Parhi, R., 2020. Drug delivery applications of chitin and chitosan: a review. Environmental chemistry letters, 18 (3), 577–594. doi: 10.1007/s10311-020-00963-5.
   Web of Science ®Google Scholar
• Parveen, S., and Sahoo, S.K., 2011. Long circulating chitosan/PEG blended PLGA nanoparticle for tumor drug delivery. European journal of pharmacology, 670 (2–3), 372–383. doi: 10.1016/j.ejphar.2011.09.023.
   PubMed Web of Science ®Google Scholar
• Patel, M.A., et al., 2017. The effect of ionotropic gelation residence time on alginatecross-linking and properties. Carbohydrate polymers, 155, 362–371. doi: 10.1016/j.carbpol.2016.08.095.
   PubMed Web of Science ®Google Scholar
• Petruk, G., et al., 2019. Encapsulation of the dinuclear trithiolato-bridged arene ruthenium complex diruthenium-1 in an apoferritin nanocage: structure and cytotoxicity. ChemMedChem. 14 (5), 594–602. doi: 10.1002/cmdc.201800805.
   PubMed Web of Science ®Google Scholar
• Poursharifi, M., Wlodarczyk, M.T., and Mieszawska, A.J., 2019. Nano-based systems and biomacromolecules as carriers for metallodrugs in anticancer therapy. Inorganics, 7 (1), 2. doi: 10.3390/inorganics7010002.
   Web of Science ®Google Scholar
• Rajaonarivony, M., et al., 1993. Development of a new drug carrier made from alginate. Journal of pharmaceutical sciences, 82 (9), 912–917. doi: 10.1002/jps.2600820909.
   PubMed Web of Science ®Google Scholar
• Ribeiro, G., et al., 2008. Diruthenium(II, III) complexes of ibuprofen, aspirin, naproxen and indomethacin non-steroidal anti-inflammatory drugs: synthesis, characterization and their effects on tumor-cell proliferation. Polyhedron, 27 (3), 1131–1137. doi: 10.1016/j.poly.2007.12.011.
   Web of Science ®Google Scholar
• Ribeiro, G., et al., 2010. The novel ruthenium-γ-linolenic complex [Ru2(aGLA)4Cl] inhibits C6 rat glioma cell proliferation and induces changes in mitochondrial membrane potential, increased reactive oxygen species generation and apoptosis in vitro. Cell biochemistry and function, 28 (1), 15–23. doi: 10.1002/cbf.1626.
   PubMed Web of Science ®Google Scholar
• Riccardi, C., et al., 2019. Anticancer ruthenium(III) complexes and Ru(III)-containing nanoformulations: an update on the mechanism of action and biological activity. Pharmaceuticals, 12 (4), 146. doi: 10.3390/ph12040146.
   Web of Science ®Google Scholar
• Rico, S.R.A., et al., 2017. Diruthenium(II,III) metallodrugs of ibuprofen and naproxen encapsulated in intravenously injectable polymer–lipid nanoparticles exhibit enhanced activity against breast and prostate cancer cells. Nanoscale, 9 (30), 10701–10714. doi: 10.1039/c7nr01582h.
   PubMed Web of Science ®Google Scholar
• Roberts, G. A. F., 1992. Chitin chemistry. London: The Macmillan Press Ltd.
   Google Scholar
• Santos, R.L.S.R., et al., 2012. Synthesis and characterization of a diruthenium(II,III)–ketoprofen compound and study of the in vitro effects on CRC cells in comparison to the naproxen and ibuprofen derivatives. Polyhedron, 42 (1), 175–181. doi: 10.1016/j.poly.2012.05.012.
   Web of Science ®Google Scholar
• Santos, R.L.S.R., Sanches, R.N.F., and de Oliveira Silva, D., 2015. Spectroscopic studies on interactions of the tetrakis(acetato)chloridodiruthenium(II,III) complex and the Ru2(II,III)-NSAID-derived metallodrugs of ibuprofen and ketoprofen with human serum albumin. Journal of coordination chemistry, 68 (17-18), 3209–3228. doi: 10.1080/00958972.2015.1074684.
   Web of Science ®Google Scholar
• Santos, R.L.S.R., van Eldik, R., and de Oliveira Silva, D., 2012. Thermodynamics of axial substitution and kinetics of reactions with amino acids for the paddlewheel complex tetrakis(acetato)chloridodiruthenium(II,III). Inorganic chemistry, 51 (12), 6615–6625. doi: 10.1021/ic300168t.
   PubMed Web of Science ®Google Scholar
• Santos, R.L.S.R., van Eldik, R., and de Oliveira Silva, D., 2013. Kinetic and mechanistic studies on reactions of diruthenium(II,III) with biologically relevant reducing agents. Dalton transactions, 42 (48), 16796–16805. doi: 10.1039/c3dt51763b.
   PubMed Web of Science ®Google Scholar
• Sarmento, B., and Neves, J., 2012. Chitosan-based systems for biopharmaceuticals-delivery, targeting and polymer therapeutics. West Sussex: John Wiley & Sons, Ltd.
   Google Scholar
• Sarmento, B., et al., 2007. Alginate/chitosan nanoparticles are effective for oral insulin delivery. Pharmaceutical research, 24 (12), 2198–2206. doi: 10.1007/s11095-007-9367-4.
   PubMed Web of Science ®Google Scholar
• Sava, G., Bergamo, A., and Dyson, P.J., 2011. Metal-based antitumour drugs in the post-genomic era: what comes next? Dalton transactions (cambridge, England: 2003), 40 (36), 9069–9075. doi: 10.1039/c1dt10522a.
   PubMed Web of Science ®Google Scholar
• Shakil, M.S., et al., 2021. Using chitosan or chitosan derivatives in cancer therapy. Polysaccharides, 2 (4), 795–816. doi: 10.3390/polysaccharides2040048.
   Google Scholar
• Sharifi‑Rad, J., et al., 2021. Chitosan nanoparticles as a promising tool in nanomedicine with particular emphasis on oncological treatment. Cancer cell international, 21, 318. doi: 10.1186/s12935-021-02025-4.
   PubMed Web of Science ®Google Scholar
• Shen, J., et al., 2021. Recent advances in ruthenium(II) and iridium(III) complexes containing nanosystems for cancer treatment and bioimaging. Coordination chemistry reviews, 443, 214016. doi: 10.1016/j.ccr.2021.214016.
   Web of Science ®Google Scholar
• Sonkar, C., Sarkar, S., and Mukhopadhyay, S., 2022. Ruthenium(ii)–arene complexes as anti-metastatic agents, and related techniques. RSC medicinal chemistry, 13 (1), 22–38. doi: 10.1039/d1md00220a.
   PubMedGoogle Scholar
• Steel, T.R., et al., 2021. Monodentately-coordinated bioactive moieties in multimodal half-sandwich organoruthenium anticancer agents. Coordination chemistry reviews, 439, 213890. doi: 10.1016/j.ccr.2021.213890.
   Web of Science ®Google Scholar
• Sudhindra, P., et al., 2022. Construction of homo and heteronuclear Ru(II), Ir(III) and Re(I) complexes for target specific cancer therapy. Coordination chemistry reviews, 460, 214462. doi: 10.1016/j.ccr.2022.214462.
   Web of Science ®Google Scholar
• Sumithaa, C., and Ganeshpandian, M., 2023. Half-sandwich ruthenium arene complexes bearing clinically approved drugs as ligands: the importance of metal − drug synergism in metallodrug design. Molecular pharmaceutics, 20 (3), 1453–1479. doi: 10.1021/acs.molpharmaceut.2c01027.
   PubMedGoogle Scholar
• Swaminathan, S., et al., 2022. Piano stool Ru(II)-arene complexes having three monodentate legs: a comprehensive review on their development as anticancer therapeutics over the past decade. Coordination chemistry reviews, 459, 214403. doi: 10.1016/j.ccr.2021.214403.
   Web of Science ®Google Scholar
• Syed, M.H., et al., 2023. An overview on recent biomedical applications of biopolymers: their role in drug delivery systems and comparison of major systems. Journal of drug delivery science and technology, 80, 104121. doi: 10.1016/j.jddst.2022.104121.
   Web of Science ®Google Scholar
• Tabares, J.P.G., et al., 2019. A Ru(II)-p-cymene compound bearing naproxen-pyridineamide. Synthesis, spectroscopic studies, computational analysis and in vitro anticancer activity against lung cells compared to Ru(II)-p-cymene-naproxen and the corresponding drug ligands. Inorganica chimica acta, 489, 27–38. doi: 10.1016/j.ica.2019.01.030.
   Web of Science ®Google Scholar
• Thangavel, P., Viswanath, B., and Kim, S., 2017. Recent developments in the nanostructured materials functionalized with ruthenium complexes for targeted drug delivery to tumors. International journal of nanomedicine, 12, 2749–2758. doi: 10.2147/IJN.S131304.
   PubMed Web of Science ®Google Scholar
• Trapani, A., et al., 2011. Methotrexate-loaded chitosan- and glycolchitosan-based nanoparticles: a promising strategy for the administration of the anticancer drug to brain tumors. AAPS PharmSciTech, 12 (4), 1302–1311. doi: 10.1208/s12249-011-9695-x.
   PubMed Web of Science ®Google Scholar
• Tremlett, W.D.J., et al., 2021. Design concepts of half-sandwich organoruthenium anticancer agents based on bidentate bioactive ligands. Coordination chemistry reviews, 445, 213950. doi: 10.1016/j.ccr.2021.213950.
   Web of Science ®Google Scholar
• Unagolla, J.M. and Jayasuriya, A.C., 2018. Drug transport mechanisms and in vitro release kinetics of vancomycin encapsulated chitosan-alginate polyelectrolyte microparticles as a controlled drug delivery system. European journal of pharmaceutical sciences, 114, 199–209. doi: 10.1016/j.ejps.2017.12.012.
   PubMed Web of Science ®Google Scholar
• Ur-Rehman, H., et al., 2016. Axially-modified paddlewheel diruthenium(II,III)-ibuprofenato metallodrugs and the influence of the structural modification on U87MG and A172 human glioma cell proliferation, apoptosis, mitosis and migration. Journal of inorganic biochemistry, 165, 181–191. doi: 10.1016/j.jinorgbio.2016.10.003.
   PubMed Web of Science ®Google Scholar
• Ur-Rehman, H., et al., 2020. Self-Assembled Nanoparticles of Diruthenium(II,III)-Ibuprofen Anticancer Metallodrug. Journal of Brazilian chemistry society, 31, 2331–2341. doi: 10.21577/0103-5053.20200091.
   Web of Science ®Google Scholar
• Villemin, E., et al., 2019. Polymer encapsulation of ruthenium complexes for biological and medicinal applications. Nature reviews chemistry, 3 (4), 261–282. doi: 10.1038/s41570-019-0088-0.
   Web of Science ®Google Scholar
• Wang, X. and Guo, Z., 2013. Targeting and delivery of platinum-based anticancer drugs. Chemical society reviews, 42 (1), 202–224. doi: 10.1039/c2cs35259a.
   PubMed Web of Science ®Google Scholar
• Wang, Y., et al., 2016. Nanoparticles of chitosan conjugated to organoruthenium complexes. Inorganic chemistry frontiers, 3 (8), 1058–1064. doi: 10.1039/C6QI00115G.
   Web of Science ®Google Scholar
• Xu, Y. and Du, Y., 2003. Effect of molecular structure of chitosan on protein delivery properties of chitosan nanoparticles. International journal of pharmaceutics, 250 (1), 215–226. doi: 10.1016/s0378-5173(02)00548-3.
   PubMed Web of Science ®Google Scholar
• Yadav, A. K., Gupta, U., and Sharma, R., 2021. Nano drug delivery strategies for the treatment of cancers. United Kingdom: Academic Press, Elsevier Inc.
   Google Scholar
• Yu, S., et al., 2019. Chitosan and chitosan coating nanoparticles for the treatment of brain disease. International journal of pharmaceutics, 560, 282–293. doi: 10.1016/j.ijpharm.2019.02.012.
   PubMed Web of Science ®Google Scholar
• Zeng, L., et al., 2017. The development of anticancer ruthenium(II) complexes: from single molecule compounds to nanomaterials. Chemical society reviews, 46 (19), 5771–5804. doi: 10.1039/c7cs00195a.
   PubMed Web of Science ®Google Scholar
• Zhang, P. and Sadler, P.J., 2017. Advances in the design of organometallic anticancer complexes. Journal of organometallic chemistry, 839, 5–14. doi: 10.1016/j.jorganchem.2017.03.038.
   Web of Science ®Google Scholar
• Zhu, X., et al., 2021. Cationic chitosan@Ruthenium dioxide hybrid nanozymes for photothermal therapy enhancing ROS-mediated eradicating multidrug resistant bacterial infection. Journal of colloid and interface science, 603, 615–632. doi: 10.1016/j.jcis.2021.06.073.
   PubMed Web of Science ®Google Scholar